This is a working overview of circular dichroism, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-13 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
== History == The syndrome is named after Edward Treacher Collins (1862–1932), the English surgeon and ophthalmologist who described its essential traits in 1900. In 1949, Adolphe Franceschetti and David Klein described the same condition on their own observations as mandibulofacial dysostosis. The term mandibulofacial dysostosis is used to describe the clinical features.
Carbohydrates: 5 to 15% of the energy consumed Protein: 20 to 30% Fats: 0 to 3% Raw celery and grapefruit are often claimed to have negative caloric balance (requiring more energy to digest than recovered from the food), with the assumption being that the thermic effect exceeds the low caloric content due to the high fibre matrix that must be unraveled to access their carbohydrates. However, there has been no research carried out to test this hypothesis and a significant amount of the thermic effect depends on the insulin sensitivity of the individual, with more insulin-sensitive individuals showing a significant TEF while individuals with increasing resistance have negligible to zero effects. The Functional Food Centre at Oxford Brookes University conducted a study into the effects of chilli peppers and medium-chain triglycerides (MCT) on Diet Induced Thermogenesis (DIT). They concluded that "adding chilli and MCT to meals increases DIT by over 50% which over time may accumulate to help induce weight loss and prevent weight gain or regain". Australia's Human Nutrition conducted a study on the effect of meal content in lean women's diets on the thermic effect of food and found that the inclusion of an ingredient containing increased soluble fibre and amylose did not reduce spontaneous food intake but rather was associated with higher subsequent energy intakes despite its reduced glycaemic and insulinemic effects.
=== Biochemical carbon concentrating mechanisms === Biochemical CCMs concentrate carbon dioxide in one temporal or spatial region, through metabolite exchange. C4 and CAM photosynthesis both use the enzyme Phosphoenolpyruvate carboxylase (PEPC) to add CO2 to a 4-carbon sugar. PEPC is faster than RuBisCO, and more selective for CO2.
=== Particle Interaction === Intermolecular forces govern the particle interaction in self-assembled systems. The forces tend to be intermolecular in type rather than ionic or covalent because ionic or covalent bonds will "lock" the assembly into non-equilibrium structures. The types intermolecular forces seen in self-assembly processes are van der Waals, hydrogen bonds, and weak polar forces, just to name a few. In self-assembly, regular structural arrangements are frequently observed, therefore there must be a balance of attractive and repulsive between molecules otherwise an equilibrium distance will not exist between the particles. The repulsive forces can be electron cloud-electron cloud overlap or electrostatic repulsion.
Sources: en.wikipedia.org
=== Treatment === Early administration (within 2–6 hours of bite) of antivenom and intubation for respiratory paralysis are keystones of management, but a chance of a hypersensivity reaction exists following antivenom administration. Neurotoxic symptoms may be irreversible once established due to the presynaptic nature of their pathology. The first taipan-specific antivenom was developed in 1954. Before this, tiger snake antivenom was used, though it was of little benefit in taipan envenomation.
the country a legion was originally recruited e.g. Italica = from Italy or peoples the legion has vanquished e.g.Parthica = victorious over the Parthians Legions bearing the personal name of an emperor, or of his gens (clan) (e.g. Augusta, Flavia) were either founded by that Emperor or awarded the name as a mark of special favour. The title Gemina means that two diminished legions have been combined to make one new one.
=== Neuropathy === Neuropathy has been a problem in some clinical trials with DCA causing them to be effectively halted, but a 2008 BJC review found that it has not occurred in other DCA trials. The mechanism of DCA induced neuropathy is not well understood. On the one hand in vitro work with nerves has suggested a mechanism for the neuropathic effect of DCA; with DCA showing a dose and exposure dependent demyelination of nerves (stripping of the nerve 'sheath'), which demyelination was partially reversible over time, following washout of DCA. On the other hand, the 2008 review in BJC states "This neurotoxicity resembled the pattern of length-dependent, axonal, sensorimotor polyneuropathy without demyelination." with regard to the 2006 study by Kaufman et al.
Sources: en.wikipedia.org
=== Catholic === American Order of United Catholics - Founded in January 1896 in New York City by Catholics who wished to counter the influence of the American Protective Association. It was "expected of the founders" that they would demand candidates for office who disapproved of the APA or other organizations that sought to discriminate against Catholics. A Supreme Council was organized on March 7, 1896, and the Order was organized "upon the usual secret society lines". They issued a circular that proclaimed that the Church did not oppose secret societies, except those that were oathbound. Catholic Aid Association - Founded in 1878 by German Catholics in Minnesota. The order began with 464 members from 10 parishes and was called the Deutsche Römisch-Katholische Unterstützungs-Gesellschaft von Minnesota; adopted its present name in 1923. Had 58,722 members in 1965, and approximately 78,000 in 1979. Headquarters in St. Paul, Minnesota. Local groups are called "subordinate Councils", of which there were 240 in 1979. Annual convention called the "Grand Council". Has rituals for initiation, installation of officers, and other purposes. Open to Roman Catholics 16-65 who are not a member of a secret society condemned by the Church. Sponsors matching grants program for Catholic elementary schools and religious education programs. Also, a College Tuition Scholarship Program has helped 800 CAA members receive degrees. Also sponsors banquets, family outings, dances, and youth activities; now Catholic United Financial.
There are a variety of career paths within the field of medical genetics, and naturally the training required for each area differs considerably. The information included in this section applies to the typical pathways in the United States and there may be differences in other countries. US practitioners in clinical, counseling, or diagnostic subspecialties generally obtain board certification through the American Board of Medical Genetics.
=== Sanger sequencing-based decoding === Although many authors implicitly envisaged a traditional Sanger sequencing-based decoding, the number of codes to sequence simply according to the complexity of the library is definitely an unrealistic task for a traditional Sanger sequencing approach. Nevertheless, the implementation of Sanger sequencing for decoding DNA-encoded chemical libraries in high-throughput fashion was the first to be described. After selection and PCR amplification of the DNA-tags of the library compounds, concatamers containing multiple coding sequences were generated and ligated into a vector. Following Sanger sequencing of a representative number of the resulting colonies revealed the frequencies of the codes present in the DNA-encoded library sample before and after selection.
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.